CL2022000790A1 - Método para tratar vih con cabotegravir y rilpivirina - Google Patents

Método para tratar vih con cabotegravir y rilpivirina

Info

Publication number
CL2022000790A1
CL2022000790A1 CL2022000790A CL2022000790A CL2022000790A1 CL 2022000790 A1 CL2022000790 A1 CL 2022000790A1 CL 2022000790 A CL2022000790 A CL 2022000790A CL 2022000790 A CL2022000790 A CL 2022000790A CL 2022000790 A1 CL2022000790 A1 CL 2022000790A1
Authority
CL
Chile
Prior art keywords
cabotegravir
rilpivirine
treat hiv
human
pharmaceutically acceptable
Prior art date
Application number
CL2022000790A
Other languages
English (en)
Inventor
Herta Maria Ludovica Crauwels
Susan L Ford
David Andrew Margolis
Stefaan Louis F Rossenu
William Robert Spreen
Solingen-Ristea Rodica Mihaela Van
Peter Evan Owen Williams
Original Assignee
Viiv Healthcare Co
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co, Janssen Sciences Ireland Unlimited Co filed Critical Viiv Healthcare Co
Publication of CL2022000790A1 publication Critical patent/CL2022000790A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención consiste en métodos para tratar VIH en un humano que los necesita, los cuales comprenden la administración de una cantidad terapéuticamente eficaz de una combinación de cabotegravir o una sal farmacéuticamente aceptable del mismo y rilpivirina o una sal farmacéuticamente aceptable de la misma, a dicho humano.
CL2022000790A 2019-10-01 2022-03-30 Método para tratar vih con cabotegravir y rilpivirina CL2022000790A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962908882P 2019-10-01 2019-10-01
US201962908995P 2019-10-01 2019-10-01
US202063037782P 2020-06-11 2020-06-11
US202063052214P 2020-07-15 2020-07-15

Publications (1)

Publication Number Publication Date
CL2022000790A1 true CL2022000790A1 (es) 2022-11-25

Family

ID=72826936

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000790A CL2022000790A1 (es) 2019-10-01 2022-03-30 Método para tratar vih con cabotegravir y rilpivirina

Country Status (11)

Country Link
US (1) US20220347174A1 (es)
EP (1) EP4037661A1 (es)
JP (1) JP2022550828A (es)
KR (1) KR20220074880A (es)
CN (1) CN114502166A (es)
AU (1) AU2020358156A1 (es)
CA (1) CA3155587A1 (es)
CL (1) CL2022000790A1 (es)
IL (1) IL290716A (es)
MX (1) MX2022003945A (es)
WO (1) WO2021064618A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222755A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
WO2023222754A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Rilpivirine for use in the treatment or prevention of hiv infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010299959B2 (en) * 2009-09-22 2016-07-21 Tibotec Pharmaceuticals Treatment and prevention of HIV infection
JP7384783B2 (ja) * 2017-07-21 2023-11-21 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物

Also Published As

Publication number Publication date
MX2022003945A (es) 2022-04-25
US20220347174A1 (en) 2022-11-03
CN114502166A (zh) 2022-05-13
CA3155587A1 (en) 2021-04-08
EP4037661A1 (en) 2022-08-10
JP2022550828A (ja) 2022-12-05
KR20220074880A (ko) 2022-06-03
IL290716A (en) 2022-04-01
AU2020358156A1 (en) 2022-04-21
WO2021064618A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2020016559A2 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
AR101740A1 (es) Terapia de combinación y composiciones
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
CO2020010013A2 (es) Terapia de combinación para tratar o prevenir el cáncer
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
CL2020002294A1 (es) Uso de un anticuerpo anti–p–selectina
DOP2017000069A (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores
ECSP19000169A (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant